case_images: PMC5397618_01
case_images: The graph shows the change of tumor size with course of treatment. The sum of the patient's tumor diameters increased after cessation of pazopanib therapy.
case_images: CRIOG2017-4801650.001.jpg
case_images: PMC5397618_01_CRIOG2017-4801650.001.jpg
case_images: fig1
case_images: Additionally, the sum of the patient's tumor diameters increased as follows: for lung metastases, by -10% (during the 3-month-pazopanib treatment) versus by 55% (during the two weeks after ceasing treatment); for liver metastases, by 0% versus by 33%; and for peritoneal dissemination, by 12% versus by 51% (Figure 1).
case_images: Transverse section of lung in computed tomography. (a) Start of pazopanib therapy. (b) End of pazopanib therapy. (c) After two weeks' cessation of pazopanib therapy.
case_images: CRIOG2017-4801650.002.jpg
case_images: PMC5397618_01_CRIOG2017-4801650.002.jpg
case_images: fig2
case_images: A CT scan taken three months after starting pazopanib treatment showed that the tumor sizes of the liver and lung metastases and of the peritoneal dissemination were stable (Figure 2). Particularly, the lung metastases sharply increased (Figure 2).